account_balance
Investment manager · 13F filer · SEC CIK 2026172
Diadema Partners LP
Reported value$283Mas of Jun 30, 2026
Positions78 29 new, 37 sold out
Top 10 weight62.5%UTHR alone is 10%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
UTHRUnited Therapeutics Corp
10.1%Added +94%
RVMDRevolution Medicines Inc
9.2%Added +72%
ABVXAbivax SA
7.6%Added +115%
COGTCogent Biosciences Inc
6.7%Added +53%
Bridgebio Pharma Inc
6.6%
BMRNBiomarin Pharmaceutical Inc
6.3%Added +111%
VKTXViking Therapeutics Inc
6.1%Trimmed −16%
EWTXEdgewise Therapeutics Inc
3.9%New
KODKodiak Sciences Inc
3.0%Added +13%
IMCRImmunocore Hldgs PLC
2.9%Added +32%
FDMT4d Molecular Therapeutics In
2.7%New
RCUSArcus Biosciences Inc
2.4%Trimmed −6%
UTHRUnited Therapeutics Corp
10.1%Added +94%
RVMDRevolution Medicines Inc
9.2%Added +72%
ABVXAbivax SA
7.6%Added +115%
COGTCogent Biosciences Inc
6.7%Added +53%
Bridgebio Pharma Inc
6.6%
Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
UTHR United Therapeutics Corp 10.1% Added +94%RVMD Revolution Medicines Inc 9.2% Added +72%ABVX Abivax SA 7.6% Added +115%COGT Cogent Biosciences Inc 6.7% Added +53%
Bridgebio Pharma Inc 6.6% Held
BMRN Biomarin Pharmaceutical Inc 6.3% Added +111%VKTX Viking Therapeutics Inc 6.1% Trimmed −16%EWTX Edgewise Therapeutics Inc 3.9% NewKOD Kodiak Sciences Inc 3.0% Added +13%IMCR Immunocore Hldgs PLC 2.9% Added +32%FDMT 4d Molecular Therapeutics In 2.7% NewRCUS Arcus Biosciences Inc 2.4% Trimmed −6%What changed